Hilar Cholangiocarcinoma Clinical Trials in Jinan, Shandong

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma